Moderna and Metagenomi to develop in vivo gene therapies
Moderna and Metagenomi have announced a collaboration to jointly create next-generation in vivo gene editing therapeutics.
List view / Grid view
Moderna and Metagenomi have announced a collaboration to jointly create next-generation in vivo gene editing therapeutics.
Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.
Scientists have discovered a novel pathway and enzyme that causes thrombosis in chronic kidney disease (CKD) patients, indicating a new drug target.
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
Turning off NHE6 in mice in pre-clinical studies prevented amyloid beta aggregation, a key feature of Alzheimer's disease, pointing to new therapies.
A new grant will allow an international team to determine if scent-processing nerves in the nose play a role in the development of Parkinson's and could aid in the development of novel therapeutics.
Professor Ulrich G Steidl received the National Institute of Cancer's Outstanding Investigator Award to study myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
The small molecule successfully targeted the C9orf72 gene that causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Researchers used Raman spectroscopy to monitor immunotherapy response in mice, potentially improving cancer treatments in the future.
Scientists have found that Hutchinson-Gilford Progeria Syndrome (HGPS) can be prevented with treatments targeting the cardiovascular system using a novel mouse model.
A new study is the first to identify N-acylethanolamine acid amidase as a new drug target to treat different forms of chronic pain.
A new gene therapy restored motor skill-learning and usual behaviours in Angelman syndrome mouse models, suggesting a novel therapy for the condition.
German, Norwegian and British scientists have identified molecular targets for therapies that could prevent breast cancer recurrence.
In an exclusive with Drug Target Review, researchers at the University at Buffalo explain how they developed a novel peptide that could be a future treatment for chronic inflammatory pain.
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.